Bexmarilimab
- Generic Name
- Bexmarilimab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2259301-27-2
- Unique Ingredient Identifier
- SA0O2AK3LA
- Background
Bexmarilimab is under investigation in clinical trial NCT03733990 (A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients).
- Associated Conditions
- -
- Associated Therapies
- -
A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-06-23
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- Faron Pharmaceuticals Ltd
- Target Recruit Count
- 181
- Registration Number
- NCT05428969
- Locations
- 🇺🇸
University of Texas, MD Anderson Cancer Center, Houston, Texas, United States
🇫🇮Tampere University Hospital, Tampere, Finland
🇺🇸City of Hope National Medical Center, Duarte, California, United States
A Phase I/II Open Label Single Centre Trial to Assess the Safety, Tolerability and Efficacy of Single Dose Neoadjuvant Anti-CLEVER-1 Antibody Bexmarilimab in Localised Renal Cell and Colon Carcinoma
- First Posted Date
- 2021-11-03
- Last Posted Date
- 2022-05-11
- Lead Sponsor
- Faron Pharmaceuticals Ltd
- Registration Number
- NCT05104905
- Locations
- 🇫🇮
Turku University Hospital, Turku, Finland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath